新入荷 再入荷

Brewer 6000 Access Hi-Lo Exam Table

flash sale icon タイムセール
終了まで
00
00
00
999円以上お買上げで送料無料(
999円以上お買上げで代引き手数料無料
通販と店舗では販売価格や税表示が異なる場合がございます。また店頭ではすでに品切れの場合もございます。予めご了承ください。
新品 9000円 (税込)
数量

商品詳細情報

管理番号 新品 :2224017666
中古 :2224017666-1
メーカー 7ab93e7 発売日 2025-04-02 16:57 定価 15000円
カテゴリ

Brewer 6000 Access Hi-Lo Exam Table

Brewer 6000 Access Hi-Lo Exam TableBrewer 6000 Access Hi-Lo Exam Table,Brewer 6000 Access Hi-Lo Exam TableBrewer 6000 Access Hi-Lo Exam Table,ASCO 2022: SKYSCRAPER-02: Primary results of a phase III, randomized,  double-blind, placebo-controlled study of atezolizumab (atezo) +  carboplatin + etoposide (CE) with or without tiragolumab (tira) in patients  (pts) with untreated extensive-stageASCO 2022: SKYSCRAPER-02: Primary results of a phase III, randomized, double-blind, placebo-controlled study of atezolizumab (atezo) + carboplatin + etoposide (CE) with or without tiragolumab (tira) in patients (pts) with untreated extensive-stage,ASCO 2023: BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug  conjugate (ADC), in patients with locally advanced or metastatic solid  tumor: Results from a first-in-human phase 1 study.ASCO 2023: BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic solid tumor: Results from a first-in-human phase 1 study.,Safety and Tolerability of AZD0466 As Monotherapy for Patients with  Advanced Hematologic Malignancies. Results from a Phase I/II Trial -  ScienceDirectSafety and Tolerability of AZD0466 As Monotherapy for Patients with Advanced Hematologic Malignancies. Results from a Phase I/II Trial - ScienceDirect

 

商品情報の訂正

このページに記載された商品情報に記載漏れや誤りなどお気づきの点がある場合は、下記訂正依頼フォームよりお願い致します。

訂正依頼フォーム

商品レビュー

レビューの投稿にはサインインが必要です